All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 2023 Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, the GvHD Hub was pleased to speak to Yi-Bin Chen, Massachusetts General Hospital, Boston, US. We asked, Is vedolizumab effective for preventing lower gastrointestinal (GI) acute graft-versus-host disease (aGvHD)?
Is vedolizumab effective for preventing lower GI acute GvHD?
Chen begins by summarizing the justifications, methods, and data from the phase III randomized, double blind, placebo-controlled GRAPHITE trial of vedolizumab. GRAPHITE was a prospective large cohort trial with a primary endpoint of lower GI aGvHD-free survival by Day 180. Chen explains the trials clinical significance, highlighting overall survival, relapse free survival, and safety.
Chen concludes by discussing the impact of current clinical trials on future treatment and prevention strategies for GvHD, as well as the impact of new interventions on patient populations.
Vedolizumab treatment for the prevention of acute GvHD following allogeneic hematopoietic stem cell transplantation
Yi-Bin Chen, Massachusetts General Hospital, Boston, US, and colleagues explored the potential benefits of coadministration of...
ASH 2018 | Vedolizumab plus standard of care to prevent graft-versus-host disease – a phase Ib study
At ASH 2018, Doctor Chen presented the 6‑month results of a phase Ib study evaluating the safety, efficacy, and tolerability of vedolizumab in...
Subscribe to get the best content related to GvHD delivered to your inbox